Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more
Pharmaron Beijing Co., Ltd. (PHBBF) - Total Assets
Latest total assets as of June 2025: $25.20 Billion USD
Based on the latest financial reports, Pharmaron Beijing Co., Ltd. (PHBBF) holds total assets worth $25.20 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmaron Beijing Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how Pharmaron Beijing Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmaron Beijing Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmaron Beijing Co., Ltd.'s total assets of $25.20 Billion consist of 31.8% current assets and 68.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.1% |
| Accounts Receivable | $2.41 Billion | 10.1% |
| Inventory | $1.12 Billion | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $791.00 Million | 3.3% |
| Goodwill | $2.76 Billion | 11.5% |
Asset Composition Trend (2020–2024)
This chart illustrates how Pharmaron Beijing Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmaron Beijing Co., Ltd.'s current assets represent 31.8% of total assets in 2024, a decrease from 46.5% in 2020.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, down from 24.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 13.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 11.5% of total assets.
Pharmaron Beijing Co., Ltd. Competitors by Total Assets
Key competitors of Pharmaron Beijing Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharmaron Beijing Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Pharmaron Beijing Co., Ltd. generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Pharmaron Beijing Co., Ltd. generates $7.49 in net profit.
Pharmaron Beijing Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 1.81 | 1.67 |
| Quick Ratio | 1.26 | 1.50 | 1.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.62 Billion | $ 3.16 Billion | $ 2.62 Billion |
Pharmaron Beijing Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Pharmaron Beijing Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.95 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | $23.93 Billion |
| Market Capitalization | $2.34 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pharmaron Beijing Co., Ltd.'s assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pharmaron Beijing Co., Ltd.'s assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmaron Beijing Co., Ltd. (2020–2024)
The table below shows the annual total assets of Pharmaron Beijing Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.93 Billion | -9.63% |
| 2023-12-31 | $26.48 Billion | +29.20% |
| 2022-12-31 | $20.49 Billion | +11.44% |
| 2021-12-31 | $18.39 Billion | +54.42% |
| 2020-12-31 | $11.91 Billion | -- |